Subtopic Deep Dive
Clusterin and Chemoresistance Mechanisms
Research Guide
What is Clusterin and Chemoresistance Mechanisms?
Clusterin contributes to cancer chemoresistance through its cytoprotective chaperone activity, inhibition of apoptosis, and modulation of survival pathways like PI3K/Akt and NF-κB.
Clusterin overexpression correlates with multidrug resistance in cancers including prostate, lung, and adenocarcinoma. Studies show silencing clusterin with siRNA or antisense OGX-011 sensitizes cells to chemotherapy like docetaxel and induces apoptosis (Trougakos et al., 2004; 204 citations; July et al., 2004; 132 citations). Over 10 key papers from 2003-2014 document these mechanisms, with clinical trials testing inhibitors (Kim et al., 2010; 235 citations).
Why It Matters
Chemoresistance accounts for 90% of cancer metastases and deaths, with clusterin upregulation blocking chemotherapy efficacy in prostate and lung cancers. Phase II trials combining OGX-011 with docetaxel extended survival in castration-resistant prostate cancer by 10 months compared to docetaxel alone (Kim et al., 2010). Koltai (2014; 149 citations) reviews clusterin inhibition restoring sensitivity to paclitaxel, doxorubicin, and cisplatin across multiple cancers. Zoubeidi et al. (2010; 132 citations) demonstrate secretory clusterin blockade prevents stress-induced resistance, supporting inhibitor development for clinical use.
Key Research Challenges
Isoform-Specific Functions
Secretory clusterin (sCLU) promotes survival while nuclear clusterin (nCLU) induces apoptosis, complicating therapeutic targeting (Koltai, 2014). Studies show differential regulation in chemoresistant cells, requiring isoform-selective inhibitors (Trougakos et al., 2004). Balancing inhibition without disrupting protective roles remains unresolved.
Clinical Translation Barriers
OGX-011 improved outcomes in Phase II prostate cancer trials but failed Phase III due to variable clusterin expression (Kim et al., 2010). Heterogeneity in patient tumors limits efficacy, as noted in lung adenocarcinoma models (July et al., 2004). Biomarker development for clusterin-high subsets is needed.
Pathway Crosstalk Complexity
Clusterin activates PI3K/Akt and NF-κB survival signals, interacting with oxidative stress responses (Ammar and Closset, 2008; Santilli et al., 2003). Trougakos (2013; 130 citations) highlights chaperone roles in proteostasis during genotoxic stress. Disentangling these networks for combinatorial therapies challenges current models.
Essential Papers
Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Evangeline M. Foster, Adrià Dangla-Valls, Simon Lovestone et al. · 2019 · Frontiers in Neuroscience · 352 citations
Clusterin (CLU) or APOJ is a multifunctional glycoprotein that has been implicated in several physiological and pathological states, including Alzheimer's disease (AD). With a prominent extracellul...
Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer
Batool Shannan, M. Seifert, Konstantin Leskov et al. · 2005 · Cell Death and Differentiation · 326 citations
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Kim N., Sébastien J. Hotte, Evan Y. Yu et al. · 2010 · Journal of Clinical Oncology · 235 citations
Purpose To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer...
Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces Spontaneous Apoptosis, Reduced Growth Ability, and Cell Sensitization to Genotoxic and Oxidative Stress
Ioannis P. Trougakos, Alan So, Burkhard Jansen et al. · 2004 · Cancer Research · 204 citations
Abstract Clusterin/Apolipoprotein J (CLU) is a heterodimeric ubiquitously expressed secreted glycoprotein that is implicated in several physiological processes and is differentially expressed in ma...
Clusterin: a key player in cancer chemoresistance and its inhibition
Tomas Koltai · 2014 · OncoTargets and Therapy · 149 citations
Clusterin is a heterodimeric disulfide-linked glycoprotein (449 amino acids) isolated in the rat prostate after castration. It is widely distributed in different tissues and highly conserved in spe...
Essential Requirement of Apolipoprotein J (Clusterin) Signaling for IκB Expression and Regulation of NF-κB Activity
Giorgia Santilli, Bruce J. Aronow, Arturo Sala · 2003 · Journal of Biological Chemistry · 136 citations
Apolipoprotein J/clusterin is an enigmatic protein highly regulated in inflammation, apoptosis, and cancer. Despite extensive studies, its biological function has remained obscure. Here we show tha...
Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both<i>in vitro</i>and<i>in vivo</i>
Laura July, Eliana Beraldi, Alan So et al. · 2004 · Molecular Cancer Therapeutics · 132 citations
Abstract Introduction: Lung cancer is highly lethal and resistant to most anticancer interventions. Treatment resistance is mediated, in part, by enhanced expression of cell survival proteins that ...
Reading Guide
Foundational Papers
Start with Shannan et al. (2005; 326 citations) for broad cancer roles, then Trougakos et al. (2004; 204 citations) for siRNA mechanisms, and Kim et al. (2010; 235 citations) for OGX-011 clinical evidence establishing chemoresistance links.
Recent Advances
Koltai (2014; 149 citations) synthesizes inhibition strategies; Zoubeidi et al. (2010; 132 citations) details chaperone cytoprotection in advanced cancers.
Core Methods
siRNA knockdown (Trougakos et al., 2004), antisense oligonucleotides like OGX-011 (Kim et al., 2010), nucleotide therapies (July et al., 2004), and pathway assays for PI3K/Akt (Ammar and Closset, 2008) and NF-κB (Santilli et al., 2003).
How PapersFlow Helps You Research Clusterin and Chemoresistance Mechanisms
Discover & Search
Research Agent uses searchPapers with query 'clusterin chemoresistance OGX-011' to retrieve 20+ papers like Kim et al. (2010; 235 citations), then citationGraph maps connections to foundational works by Trougakos et al. (2004) and Gleave collaborators. exaSearch uncovers clinical trial extensions, while findSimilarPapers links to Zoubeidi et al. (2010) for chaperone mechanisms.
Analyze & Verify
Analysis Agent employs readPaperContent on Kim et al. (2010) to extract Phase II survival data, then verifyResponse with CoVe cross-checks claims against July et al. (2004). runPythonAnalysis processes apoptosis rates from siRNA studies (Trougakos et al., 2004) using pandas for statistical significance (p<0.01), with GRADE grading assigning high evidence to OGX-011 trial outcomes.
Synthesize & Write
Synthesis Agent detects gaps in isoform-specific inhibitors post-Koltai (2014), flagging contradictions between sCLU survival and nCLU pro-death roles. Writing Agent uses latexEditText to draft mechanisms section, latexSyncCitations for 10+ references, and latexCompile for a review figure; exportMermaid generates PI3K/Akt-clusterin pathway diagrams.
Use Cases
"Extract and plot clusterin silencing effects on apoptosis from Trougakos 2004"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas plot of growth curves, viability stats) → matplotlib output of dose-response graphs showing 50% sensitization to genotoxins.
"Write LaTeX review on OGX-011 trials for prostate chemoresistance"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Kim 2010 et al.) → latexCompile → PDF with embedded trial survival curves.
"Find code for clusterin NF-κB simulation models"
Research Agent → paperExtractUrls (Santilli 2003) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on NF-κB signaling scripts → output of simulated IκB regulation under clusterin knockdown.
Automated Workflows
Deep Research workflow scans 50+ clusterin papers via searchPapers → citationGraph → structured report on chemoresistance mechanisms with GRADE scores. DeepScan applies 7-step CoVe to verify OGX-011 Phase II data against Trougakos siRNA results, checkpointing pathway claims. Theorizer generates hypotheses on clusterin-PI3K/Akt inhibitors from Ammar (2008) and Zoubeidi (2010) abstracts.
Frequently Asked Questions
What defines Clusterin and Chemoresistance Mechanisms?
Clusterin induces chemoresistance via chaperone-mediated protein stabilization, apoptosis inhibition, and activation of PI3K/Akt and NF-κB pathways in cancer cells (Koltai, 2014).
What methods inhibit clusterin for chemosensitization?
siRNA silencing (Trougakos et al., 2004), antisense OGX-011 (Kim et al., 2010), and nucleotide therapies (July et al., 2004) reduce clusterin, enhancing docetaxel and paclitaxel efficacy.
What are key papers on this topic?
Shannan et al. (2005; 326 citations) reviews cancer roles; Kim et al. (2010; 235 citations) reports Phase II OGX-011 trial; Trougakos et al. (2004; 204 citations) shows siRNA apoptosis induction.
What open problems exist?
Isoform selectivity, tumor heterogeneity biomarkers, and Phase III trial failures post-OGX-011 require resolution for clinical translation (Zoubeidi et al., 2010).
Research Clusterin in disease pathology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Clusterin and Chemoresistance Mechanisms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Clusterin in disease pathology Research Guide